transporter among the various efflux and influx carriers involved in the cellular trafficking of imatinib in vitro.
Our analysis thus clearly confirms that the restoration of imatinib sensitivity observed in the imatinib-resistant CML cell lines K562/Dox subjected to MDR1 gene silencing 7 is the result of a marked increase in imatinib intracellular disposition. This is in agreement with the observation of Mahon et al., 4 but not with the conclusions of Ferrao et al. 5 and Zong et al. 6 concerning the role played by MDR1 in imatinib resistance. In the Ferrao study, 5 however, the effect of verapamil on the hOCT1 transporter, or the expression level thereof, may have represented a confounding factor. In the study of Zong et al., 6 the validity of the murine model used has already been debated. 3 In fact, Zong et al. suggested that the discrepancies between various experiments are explained by redundant efflux mechanism of imatinib. 3 We provide here additional evidences that imatinib cellular disposition has to be considered on a wide perspective, integrating not only efflux, but also influx transporters, which are critical determinants of imatinib intracellular availability, and which probably condition in part resistance to the drug. This is supported by the recent findings that the expression level of hOCT1, 2 or the ex vivo drug uptake, 1 in CML patients represents prognostic indices for imatinib response. Such observations are not incompatible with the restoration of sensitivity by MDR1 inhibition observed by Rumpold et al. The letter of Widmer et al. describes that the silencing of MDR1 expression by specific small interfering RNA (siRNA) resulted in the increased intracellular levels of imatinib in doxorubicinselected K562 cells. 1 Their finding is consistent with the previously reported concept that imatinib is a substrate for P-glycoprotein (P-gp), 2, 3 and rules out other possibilities that could lead to restoration of imatinib sensitivity. However, we found that specific elimination of P-gp expression in the Table 1 Concentration of imatinib in P-gp+ and P-gpÀ (MDR1-RNAi knockdown) cells at various imatinib incubation levels Phenotype Incubation medium (mg/ml) Intracell (mg/ml) Extracell (mg/ml) Intra/extracell ratio Letters to the Editor hematopoietic system did not improve responses to imatinib in a chronic myelogenous leukemia (CML) animal model; leukemia initiating cells were not sensitized to imatinib by loss of P-gp, indicating the negligible role of P-gp in resistance to imatinib in vivo. 4 In line with our findings, a recent study in patients with gastrointestinal stromal tumors (GIST) showed that the pharmacokinetic parameters of imatinib in vivo were not related to any of the defective variant genotypes of ABCG2 or MDR1 alleles examined, indicating the activity of these two ATP-binding cassette (ABC) transporters have limited clinical significance on the pharmacokinetics of imatinib. 5 Consistently, in another study of 21 GIST patients, no significant correlation between ABC transporters expression and the risk assessment was observed; none of the six patients treated with imatinib were resistant, although all were positive for expression of at least one ABC transporter. 6 As discussed previously, the contribution of P-gp expression to clinical imatinib resistance in CML also appears to be limited. 7 We proposed that this paradox could be possibly explained by the inhibitory effects of imatinib on the efflux function of P-gp and other ABC transporters. We (data not shown) and others 3, 8, 9 found that incubation with high concentrations of imatinib led to potent functional inhibition of P-gp as well as ABCG2. Given the similar molecular structures between imatinib and ATP, it is possible that the abrogation of transporter function may result from competitive binding of imatinib to ATP-binding sites on the nucleotide-binding domain of ABC transporters, which could make the ABC transporter-expressing cells display an ABC transporter null phenotype. Moreover, Nakanishi et al. 10 recently described that ABCG2-overepressing K562 cells only displayed modest resistance to the low concentration of imatinib. It has been also showed that imatinib could decrease the expression of ABCG2 post-transcriptionally in BCR-ABL positive cells, and this downregulation of ABCG2 expression may occur via inhibition of PI3K/Akt pathway. So imatinibinduced reduction of ABCG2 protein expression could also attenuate the resistance to imatinib. 10 Taken together, it seems that imatinib can abolish the protective effects of ABC transporters by both ATP depletion and downregulation of transporter expression, which make the interaction of imatinib with ABC transporters more complicated than it appears to be. Therefore, more studies are required to dissect carefully this complexity in different contexts. The arguments presented by Zong et al.
1,2 on the controversial role of P-glycoprotein (P-gp) are relevant. We agree that there is no evidence at present that this transporter represents per se a major resistance factor in vivo. In fact, in our recent clinical study we have shown that the MDR1 (ABCB1) 3435C4T polymorphism, associated with altered P-gp expression, tends to influence imatinib systemic pharmacokinetics, albeit not significantly.
3 P-gp probably contributes to resistance but is not solely responsible for that.
The various transporters involved in imatinib systemic, tissular and cellular disposition are characterized by competing and/or opposite effects. Focusing thus only on efflux transporters (i.e. ABCB1 and ABCG2) in in vitro cell systems certainly provides an incomplete picture of the complex and delicate influx-and efflux-balance existing in vivo. However, an indirect and important finding of our in vitro experiments, in which MDR1 expression and function has been specifically silenced by RNAi, was that they allow to reveal the remarkable accumulation of imatinib in cells. This suggests an important role for influx drug transporters on imatinib cellular disposition. 4 Influx transporters -such as human organic transporter 1 -may indeed also contribute to influence imatinib clinical response, as suggested
